The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Miocamycin     [(2S,3S,4R,6S)-4-acetyloxy-6- [(2R,3S,4S,5R...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Miocamycin


High impact information on Miocamycin

  • Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain [3].
  • The results of this study suggest that dirithromycin has comparable safety and efficacy to miocamycin in the treatment of streptococcal pharyngitis/tonsillitis infections caused by Group A streptococci [4].
  • The efforts expended in chemical and biochemical modifications of 16-membered macrolides have been less successful, with only a few new molecules, such as rokitamycin and miocamycin, showing improved bioavailability and activity against some resistant micro-organisms.(ABSTRACT TRUNCATED AT 250 WORDS)[5]
  • Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms [6].
  • The effect of ponsinomycin (or miocamycin), a new macrolide antibiotic, was investigated on the pharmacokinetics of carbamazepine (CBZ) administered as a single dose in healthy volunteers [7].

Chemical compound and disease context of Miocamycin


Biological context of Miocamycin


Anatomical context of Miocamycin

  • The highest levels of miocamycin were observed after 2h in tonsils (3.2 +/- 0.82 mg/kg) and serum (1.3 +/- 0.33 mg/l) [13].
  • Miocamycin reached the highest concentration in the endometrium (2.5 micrograms/g) and the lowest in the vagina (1.1-0.8 micrograms/g) [14].
  • A group of 18 patients, before undergoing otoplastic surgery, was treated with miocamycin 600 mg in a single dose; middle ear tissue samples were collected at 2, 3, 4 and 6 h [15].
  • At the following experimental times of withdrawal, the miocamycin concentration in mucosa specimens, as well as in MEF samples, proved to be markedly higher than values simultaneously found in serum [15].
  • The natural killer cell activity of patients treated with miocamycin was increased on days 7 and 10 of therapy compared with baseline [16].

Associations of Miocamycin with other chemical compounds


Gene context of Miocamycin


Analytical, diagnostic and therapeutic context of Miocamycin


  1. Miocamycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Holliday, S.M., Faulds, D. Drugs (1993) [Pubmed]
  2. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Hardy, D.J., Hensey, D.M., Beyer, J.M., Vojtko, C., McDonald, E.J., Fernandes, P.B. Antimicrob. Agents Chemother. (1988) [Pubmed]
  3. Significant increase in the prevalence of erythromycin-resistant, clindamycin- and miocamycin-susceptible (M phenotype) Streptococcus pyogenes in Spain. Alós, J.I., Aracil, B., Oteo, J., Gómez-Garcés, J.L. J. Antimicrob. Chemother. (2003) [Pubmed]
  4. Clinical efficacy of dirithromycin versus miocamycin in tonsillopharyngitis. Ruggiero, G., Utili, R., Adinolfi, L.E., Attanasio, V., Scarano, M.P., Mazzone, A., Costa, G., Califano, L., Costa, F. J. Antimicrob. Chemother. (1993) [Pubmed]
  5. Chemistry and mode of action of macrolides. Mazzei, T., Mini, E., Novelli, A., Periti, P. J. Antimicrob. Chemother. (1993) [Pubmed]
  6. Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms. Kasahara, M., Suzuki, H., Komiya, I. Drug Metab. Dispos. (2000) [Pubmed]
  7. Effect of ponsinomycin on single-dose kinetics and metabolism of carbamazepine. Couet, W., Istin, B., Ingrand, I., Girault, J., Fourtillan, J.B. Therapeutic drug monitoring. (1990) [Pubmed]
  8. Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-11. Toxicity of metabolites of miocamycin: acute toxicity of Mb12 in rats. Yokota, M., Takeda, U., Odaki, M., Sasaki, H., Kawaoto, H., Watanabe, H., Ishiwatari, N., Koeda, T. The Japanese journal of antibiotics. (1984) [Pubmed]
  9. Kidney graft dysfunction after drug interaction between miocamycin and cyclosporin. Treille, S., Quoidbach, A., Demol, H., Juvenois, A., Dehout, F., Abramowicz, D. Transpl. Int. (1999) [Pubmed]
  10. Streptococcal pharyngitis in Italian children: epidemiology and treatment with miocamycin. Principi, N., Marchisio, P., Calanchi, A., Onorato, J., Plebani, A., Reali, E., Rancilio, L., Grasso, E., Magni, L., Caramia, G. Drugs under experimental and clinical research. (1990) [Pubmed]
  11. Miocamycin in chlamydia trachomatis infections in neonatology: clinical results, pharmacokinetics and microbiological evaluation. Clerici, D., Garlaschi, C., Varotto, F., Marini, A., Scaglione, F., Fraschini, F. Journal of chemotherapy (Florence, Italy) (1989) [Pubmed]
  12. Activities of human alveolar macrophages (HAMs). Note 1: Observations on phagocytosis and bacterial killing in the presence of miocamycin. Capelli, A., Capelli, O., Azzolini, L., Richeldi, L., Prandi, E., Velluti, G. Chemioterapia : international journal of the Mediterranean Society of Chemotherapy. (1988) [Pubmed]
  13. Miocamycin distribution in tonsillar and pulmonary tissues after repeated administration. Scaglione, F., Falchi, M., Nebuloni, R., Cattaneo, G., Pintucci, J.P., Mezzetti, M., Zampella, K., Saudelli, M., Casini, A., Fraschini, F. Journal of chemotherapy (Florence, Italy) (1990) [Pubmed]
  14. Some pharmacokinetic data on miocamycin II. Concentrations in gynaecological tissues. Furneri, P.M., Cianci, A., Garozzo, A., Roccasalva, L., Pinizzotto, M.R., Palumbo, G., Tempera, G. Drugs under experimental and clinical research. (1991) [Pubmed]
  15. Kinetic profile of miocamycin in middle ear fluid and mucosa. Fraschini, F., Scaglione, F., Falchi, M., Nebuloni, R., Zampella, K., Saudelli, M., De Luca, M., Casini, A., Pintucci, G.P. Acta Otolaryngol. (1991) [Pubmed]
  16. Comparison of miocamycin versus amoxycillin in lower respiratory tract infections in children. Clinical response and effect on natural killer activity. Agostoni, C., Giovannini, M., Fraschini, F., Scaglione, F., Galluzzo, C., Riva, E., Ferrara, F. J. Int. Med. Res. (1988) [Pubmed]
  17. Effect of miocamycin on theophylline kinetics in children. Principi, N., Onorato, J., Giuliani, M.G., Vigano, A. Eur. J. Clin. Pharmacol. (1987) [Pubmed]
  18. Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis. Bozdogan, B., Appelbaum, P.C., Ednie, L., Grivea, I.N., Syrogiannopoulos, G.A. Clin. Microbiol. Infect. (2003) [Pubmed]
  19. In-vitro postantibiotic effects of miocamycin and erythromycin on gram-positive cocci. Varotto, F., Garlaschi, M.L., Garlaschi, M.C., Falchi, M., Scaglione, F., Cattaneo, G., De Luca, M., Fraschini, F. Journal of chemotherapy (Florence, Italy) (1990) [Pubmed]
WikiGenes - Universities